Hepatitis B Trial, Recruiting NCT06746701 Sponsor: Xiangya Hospital of Central South University Condition: Hepatitis B
Back to Hepatitis B

Hepatitis B Trial, Recruiting

NCT06746701
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 65 years (any gender)
  • People who have tested positive for the hepatitis B surface antigen (a marker of hepatitis B infection) for at least 6 months
  • People who have a family history of liver cancer, meaning at least one close or extended family member (such as a parent, child, sibling, grandparent, aunt, uncle, or great-grandparent) has had liver cancer
  • People who are planning to receive, or are already receiving, a specific hepatitis B treatment — either a combination of Peginterferon alpha-2b and antiviral tablets, or antiviral tablets alone (confirm with trial site for exact medications)
  • Women who could become pregnant must have had a negative pregnancy test within 24 hours before the first treatment dose
  • People who are willing to receive the study treatment and sign a consent form

Who may not be able to join:

  • People who have a known allergy to interferon
  • People who have previously used a medication called telbivudine as part of antiviral treatment
  • People whose liver enzyme (ALT) levels are more than 10 times the accepted normal range, or whose bilirubin levels are more than twice the normal range (confirm with trial site)
  • People who have advanced liver disease where the liver is no longer functioning properly (sometimes called decompensated cirrhosis)
  • People with low white blood cell counts or low platelet counts below certain levels (confirm with trial site for specific thresholds)
  • People with serious conditions affecting the heart, lungs, kidneys, brain, or eyes
  • People with autoimmune diseases, psychiatric disorders, poorly controlled diabetes, or thyroid problems (overactive or underactive thyroid)
  • People who have been diagnosed with, or are suspected of having, liver cancer or any other type of cancer
  • People who have had an organ transplant or are being prepared for one
  • People who are currently taking medications that suppress the immune system
  • Women who are pregnant or planning to become pregnant within the next 2 years
  • People with alcohol or drug dependency
  • People who are also infected with HIV
  • People whose doctor considers interferon treatment to be unsuitable for them for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: LeDu Zhou, Ph.D, Xiangya Hospital of Central South University

Phone: 17373120367

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Xiangya Hospital of Central South University
Registry
ClinicalTrials.gov
Start date
25 May 2023
Est. completion
25 May 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Clinical cure rate; Liver cancer incidence rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov